Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies

Author(s): S. Espuelas, D. Plano, P. Nguewa, M. Font, J.A. Palop, J.M. Irache, C. Sanmartin

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 25 , 2012

Become EABM
Become Reviewer

Abstract:

The protozoan diseases leishmaniasis, human African trypanosomiasis (HAT) and Chagas disease (CD) are responsible for substantial global morbidity and mortality in tropical and subtropical regions. Environmental changes, drug resistance and immunosuppression are contributing to the emergence and spread of these diseases. In the absence of safe and efficient vaccines, chemotherapy, together with vector control, remains the most important measure to control kinetoplastid diseases. Nevertheless, the current chemotherapeutic treatments are clearly inadequate because of their toxic effects, generation of resistances as well as route and schedules of administration not adapted to the field-conditions. This review overlooks the strategies that can be addressed to meet immediately the patient needs such as the reconsideration of current regimens of administration and the rational combination of drugs in use. In the medium-long term, due to new methodologies of medicinal-chemistry, the screening from natural products and the identification of new therapeutic targets, new lead compounds have great chance to advance through the drug development pipeline to clinic. Modern pharmaceutical formulation strategies and nanomedicines also merit a place in view of the benefits of a single dose of liposomal Amphotericin B (AmBisome ®) against visceral leishmaniasis. BBB-targeted nanodevices could be suited for selective delivery of drugs against HAT encephalitic phase. Bioadhesive nanoparticles can be proposed to enhance the bioavailability of drugs after oral administration by reason of improving the drug solubility, and permeability across the intestinal epithelia.

Keywords: Chagas disease, chemotherapy, human African trypanosomiasis, drug delivery systems, leishmaniasis, oral administration, selenium derivatives, protozoan diseases leishmaniasis, nanomedicines

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 25
Year: 2012
Published on: 12 September, 2012
Page: [4259 - 4288]
Pages: 30
DOI: 10.2174/092986712802884222
Price: $65

Article Metrics

PDF: 42